Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
249 results:
1. The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study.
Zhang C; Shao J; Tang X; Wu J; Li P; Li W; Wang C
Int Immunopharmacol; 2024 Jun; 134():112152. PubMed ID: 38761777
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (egfr) tyrosine kinase inhibitors as the first line therapy in susceptible egfr-mutated advanced non-small-cell lung.
Kuo CY; Tsai MJ; Hung JY; Lee MH; Wu KL; Tsai YC; Chuang CH; Huang CW; Chen CL; Yang CJ; Chong IW
Kaohsiung J Med Sci; 2024 May; 40(5):467-476. PubMed ID: 38523603
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
4. [clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
5. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With egfr-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
6. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in egfr-mutated lung cancer.
Wu YY; Hsu YL; Huang YC; Su YC; Wu KL; Chang CY; Ong CT; Lai JC; Shen TY; Lee TH; Hung JY; Tsai YM
Theranostics; 2023; 13(13):4412-4429. PubMed ID: 37649596
[No Abstract] [Full Text] [Related]
8. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic egfr-Mutant NSCLC (egfr+ NSCLC): Association Between TP53 Status and clinical outcome.
Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
[TBL] [Abstract] [Full Text] [Related]
9. The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM; Dietzen M; Al Bakir M; Lim EL; Karasaki T; Ward S; Veeriah S; Colliver E; Huebner A; Bunkum A; Hill MS; Grigoriadis K; Moore DA; Black JRM; Liu WK; Thol K; Pich O; Watkins TBK; Naceur-Lombardelli C; Cook DE; Salgado R; Wilson GA; Bailey C; Angelova M; Bentham R; Martínez-Ruiz C; Abbosh C; Nicholson AG; Le Quesne J; Biswas D; Rosenthal R; Puttick C; Hessey S; Lee C; Prymas P; Toncheva A; Smith J; Xing W; Nicod J; Price G; Kerr KM; Naidu B; Middleton G; Blyth KG; Fennell DA; Forster MD; Lee SM; Falzon M; Hewish M; Shackcloth MJ; Lim E; Benafif S; Russell P; Boleti E; Krebs MG; Lester JF; Papadatos-Pastos D; Ahmad T; Thakrar RM; Lawrence D; Navani N; Janes SM; Dive C; Blackhall FH; Summers Y; Cave J; Marafioti T; Herrero J; Quezada SA; Peggs KS; Schwarz RF; Van Loo P; Miedema DM; Birkbak NJ; Hiley CT; Hackshaw A; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):525-533. PubMed ID: 37046096
[TBL] [Abstract] [Full Text] [Related]
10. Resistance to immune checkpoint inhibitors in advanced lung cancer: clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-small cell lung cancer.
Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor.
Machado-Rugolo J; Baldavira CM; Prieto TG; Olivieri EHR; Fabro AT; Rainho CA; Castelli EC; Ribolla PEM; Ab'Saber AM; Takagaki T; Nagai MA; Capelozzi VL
Braz J Med Biol Res; 2023; 55():e12409. PubMed ID: 36629526
[TBL] [Abstract] [Full Text] [Related]
13. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
14. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
15. Rare egfr E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
Huang Y; Xu C; Sun Y; Wang W; Li X; Liao J; Pang L; Zeng L; Li J; Wang X; Zhang Q; Xie Z; Xiao L; Gan J; Fang W
Lung Cancer; 2022 Oct; 172():117-123. PubMed ID: 36063602
[TBL] [Abstract] [Full Text] [Related]
16. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare egfr extracellular domain M277E mutation and high PD-L1 expression.
Lv D; Wang R; Wang X; Feng H
J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
[TBL] [Abstract] [Full Text] [Related]
17. Driver Mutation Variant Allele Frequency in Circulating Tumor DNA and Association with clinical outcome in Patients with Non-small cell lung cancer and egfr- and KRAS-Mutated Tumors.
Li M; Yang L; Hughes J; van den Hout A; Burns C; Woodhouse R; Dennis L; Hegde P; Oxnard GR; Vietz C
J Mol Diagn; 2022 May; 24(5):543-553. PubMed ID: 35301118
[TBL] [Abstract] [Full Text] [Related]
18. Treatment outcome of atypical egfr mutations in the German National Network Genomic Medicine lung cancer (nNGM).
Janning M; Süptitz J; Albers-Leischner C; Delpy P; Tufman A; Velthaus-Rusik JL; Reck M; Jung A; Kauffmann-Guerrero D; Bonzheim I; Brändlein S; Hummel HD; Wiesweg M; Schildhaus HU; Stratmann JA; Sebastian M; Alt J; Buth J; Esposito I; Berger J; Tögel L; Saalfeld FC; Wermke M; Merkelbach-Bruse S; Hillmer AM; Klauschen F; Bokemeyer C; Buettner R; Wolf J; Loges S;
Ann Oncol; 2022 Jun; 33(6):602-615. PubMed ID: 35263633
[TBL] [Abstract] [Full Text] [Related]
19. Role of Circulating Tumor DNA Profiling in Patients with Non-small cell lung cancer Treated with egfr Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of egfr mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
Zeng Y; Guo T; Zhou Y; Zhao Y; Chu L; Chu X; Yang X; Ni J; Zhu Z
BMC Cancer; 2022 Feb; 22(1):198. PubMed ID: 35189835
[TBL] [Abstract] [Full Text] [Related]
[Next]
